Results :
No patients were lost during follow-up.
Very few side effects were reported: 2 patients (6.7%) experienced a severe worsening of their pain in the immediate post-operative period. Both patients were then significantly improved by their first follow-up visit at 8 weeks.
VAS scores were significantly improved (Table 2) for dysmenorrhoea (80 vs 25: p=0.001), dyspareunia (71 vs 28: p=0.02), and pelvic pain outside of menstruation (67 vs 28: p=0.03). Quality of life scores all improved dramatically. The sexual activity questionnaire scores also improved, with a significantly reduced level of discomfort (4.8 vs. 2.2: p=0.02) and improvement in habit (0,2 vs 1,9: p=0,03). 9 patients (30%) had positive criteria for pelvic hypersensitivity. In this group, the improvement was not significant for all scores.
In this study’s follow-up, 39% of patients were given new injections before the reappearance of PUS.